Download MendeleyDiscovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen.
Bukhtiyarova, M., Cook, E.M., Hancock, P.J., Hruza, A.W., Shaw, A.W., Adam, G.C., Barnard, R.J.O., McKenna, P.M., Holloway, M.K., Bell, I.M., Carroll, S., Cornella-Taracido, I., Cox, C.D., Kutchukian, P.S., Powell, D.A., Strickland, C., Trotter, B.W., Tudor, M., Wolkenberg, S., Li, J., Tellers, D.M.(2021) ACS Med Chem Lett 12: 99-106
- PubMed: 33488970 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acsmedchemlett.0c00551
- Primary Citation Related Structures:
7RN5, 7RNI - PubMed Abstract:
By employing a phenotypic screen, a set of compounds, exemplified by 1 , were identified which potentiate the ability of histone deacetylase inhibitor vorinostat to reverse HIV latency. Proteome enrichment followed by quantitative mass spectrometric analysis employing a modified analogue of 1 as affinity bait identified farnesyl transferase (FTase) as the primary interacting protein in cell lysates. This ligand-FTase binding interaction was confirmed via X-ray crystallography and temperature dependent fluorescence studies, despite 1 lacking structural and binding similarity to known FTase inhibitors. Although multiple lines of evidence established the binding interaction, these ligands exhibited minimal inhibitory activity in a cell-free biochemical FTase inhibition assay. Subsequent modification of the biochemical assay by increasing anion concentration demonstrated FTase inhibitory activity in this novel class. We propose 1 binds together with the anion in the active site to inhibit farnesyl transferase. Implications for phenotypic screening deconvolution and HIV reactivation are discussed.
- MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
Organizational Affiliation:
